Toxoplasmosis Treatment Drugs Market Size Estimation, Top Key Players and Future Trends | Vyera Pharmaceuticals, Taj Accura Pharmaceuticals, Mangalam Drugs and Organics, Cerovene Healthcare, Greenstone, Amneal Pharmaceuticals
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Toxoplasmosis is an infection caused by parasite toxoplasma gondi. Moreover, toxoplasma gondi parasites are present in contaminated food. Moreover, accidental swallowing of the parasite spread through various sources like contact of cat feces, any infected blood, through infected organ transplantation, and drinking contaminated water, which can also cause toxoplasmosis infection. Toxoplasmosis infections can transmit toxoplasma gondi from the mother to child during pregnancy. Most patients suffering from toxoplasmosis infection recover without treatment but in case of serious toxoplasmosis infection, combination of pyrimethamine and sulfadiazine are usually prescribed by doctors. Additionally, the pyrimethazine drug also reduces the level of folic acid in patients, therefore, Vitamin B supplement is recommended along with pyrimethamine drug.
Patients suffering from AIDS or HIV and toxoplasmosis may have to continue medication such as pyrimethamine for rest of their lives. Spiramycin is usually prescribed by the doctor in first and early second trimester stage of pregnancy to reduce the transmission of infection to the fetus. During the last and third trimester stage, a combination of pyrimethamine/sulfadiazine and leucovorin is prescribed for pregnancy cases.
Global Toxoplasmosis Treatment Drugs Market: Drivers
The global toxoplasmosis treatment drugs market is expected to witness significant growth during the forecast period as pharmaceutical companies are focusing on research and development of treatments for toxoplasmosis. For instance, in 2018, Vyera Pharmaceuticals LLC received the U.S. Food Drug and Administration (FDA) clearance to initiate Phase 1 study of the VYR-006, which is a potent dihydrofolate reductase (DHFR) inhibitor used for treatment of toxoplasmosis.
Moreover, the growing prevalence of HIV across the globe is increasing risk of toxoplasma gonad infection due to less immune response in HIV-infected patients. For instance, according to the World Health Organization (WHO), by the end of 2018, around 37.9 million people across the globe had HIV, therefore it is expected to increase prevalence of toxoplasmosis infection among the global population.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4166
Global Toxoplasmosis Treatment Drugs: COVID-19 Impact Analysis
The COVID-19 pandemic has impacted growth of several markets across the globe and it is also expected to hamper the growth of the global toxoplasmosis treatment drugs market during the forecast period. Moreover, safety precautions suggested by the World Health Organization to reduce the spread of COVID-19 and implementation of nationwide lockdowns have affected the supply chain of toxoplasmosis treatment drugs due to higher shipping prices because of reduced excipient supply containers.
Global Toxoplasmosis Treatment Drugs Market: Restraints
The use of pyrimethanine and sulfadiazine drugs are characterized by side effects in pregnant women such as injury to the fetus and bone marrow suppression. Moreover, according to U.S. Food Drug and Administration’s February 2020 report, the most common side effect of pyrimethamine is hypersensitivity, which leads to severe diseases such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Furthermore, low dosage of promethazine can also cause hematologic effects in patients. These factors are expected to restrain growth of the global toxoplasmosis treatment drugs market.
Global Toxoplasmosis Treatment Drugs Market: Regional Analysis
On the basis of region, the global toxoplasmosis treatment drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In 2020, North America is expected to account the largest market share in the global toxoplasmosis treatment drugs market owing to factors such as the increasing prevalence of toxoplasmosis infection. According to the Centers for Disease Control and Prevention’s September 2018 report, in the U.S, around 11% of the population in the age group of 6 or older suffered from toxoplasma.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/4166
Furthermore, pharmaceutical companies are focusing on research and development of effective treatments for toxoplasmosis to strengthen their market share in the global toxoplasmosis treatment drugs market. For instance, in February 2020, Cerovene Inc. obtained approval for generic Daraprim (pyrimethamine) tablet for treatment of toxoplasmosis from the U.S. FDA. The drug is used with combination of sulfonamide for treatment of toxoplasmosis bacterial infection.
Europe is expected to witness significant growth in the global toxoplasmosis treatment drugs market due to the rising prevalence of HIV in Europe. For instance, according to the World Health Organization’s 2018 report, over 2 million people in Europe were affected by HIV.
Global Toxoplasmosis Treatment Drugs Market: Key Players
Key players operating in the global toxoplasmosis treatment drugs market are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.
Need a discount?
Note: *The discount is offered on the Standard Price of the report.
Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/4166
On the basis of indication, the global toxoplasmosis treatment drugs market is segmented into:
- Chronic Toxoplasmosis Infection
- Acute Toxoplasmosis Infection
On the basis of route of administration, the global toxoplasmosis treatment drugs market is segmented into:
- Parental Route
- Oral Route
On the basis of drug class, the global toxoplasmosis treatment drugs market is segmented into:
On the basis of distribution channel, the global toxoplasmosis treatment drugs market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
On the basis of region, the global toxoplasmosis treatment drugs market is segmented into:
- North America
- Latin America
- Middle East
- Asia Pacific
Other Related Reports:
Sulfadiazine Sodium Injection Market, by Product Type (20mg/mL, 40mg/mL, others), by Patient Type (Human, and Animal), By Indication (Toxoplasmosis, Acute Otitis Media (AOM), Chancroid, Chlamydial Infections, Haemophilus Influenzae Infections, Malaria, Neisseria Meningitides Infections, Plague, Urinary Tract Infections), By End User (Hospitals, Clinics, Medical Centers, and Veterinary), and by Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis 2018 – 2026
Antiparasitic Drugs Market, by Drug Class (Anthelmintics (Benzimidazoles, Pyrantel, Niclosamide, Praziquantel, and Others), Antiprotozoals (Antimalarial Drugs-Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and sulfones, Others), and Other Antiprotozoal Agents), and Others (Pediculocides & miticulocides) (Lindane, Malathion, Pyrethrins, and Others), By Route of Administration (Oral, Injectable, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Anti-malarial Drugs Market, by Drug Class (Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and Sulfones, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire